PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
The plant will drive pharmaceutical innovation in the Northeastern India
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
iSolveSM information on demand is the result of our focus on customer relationship
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
Subscribe To Our Newsletter & Stay Updated
